Forest plot showing the odds ratio (OR) of proportion of eyes that lost of one or more lines of best spectacle corrected visual acuity (BSCVA) comparing small incision lenticule extraction (SMILE) with femtosecond laser-assisted LASIK (FS-LASIK) within six months postoperatively.

<p>The diamonds represent the summary estimates of all five studies or the subgroup analysis of two RCTs and three cohorts.</p

Forest plot showing the odds ratio (OR) of proportion of eyes within ±1.0 D of target refraction comparing small incision lenticule extraction (SMILE) with femtosecond laser-assisted LASIK (FS-LASIK) within six months postoperatively.

<p>The diamonds represent the summary estimates of all three studies or the subgroup analysis of one RCT and two cohorts.</p

Forest plot showing the odds ratio (OR) of proportion of eyes with uncorrected visual acuity (UCVA) 20/20 or better comparing small incision lenticule extraction (SMILE) with femtosecond laser-assisted LASIK (FS-LASIK) within six months postoperatively.

<p>The diamonds represent the summary estimates of all six studies or the subgroup analysis of three RCTs and three cohorts.</p

Characteristics of Studies Included in the Meta-analysis Comparing the SMILE and FS-LASIK.

<p>SMILE = small incision lenticule extraction, FS-LASIK = femtosecond laser-assisted LASIK, SE = spherical equivalent.</p

Subgroup Analyses on Region.

<p>BSCVA = best spectacle corrected visual acuity, UCVA = uncorrected visual acuity, SE = spherical equivalent, OR = odds ratio, MD = mean difference, CI = confidence interval, I² = extent of inconsistency.</p

Hydroclathrus cancellatus Bory

原著和名: カゴメノリ科名: カヤモノリ科 = Scytosiphonaceae採集地: 千葉県 安房郡 館山町 沖ノ島 (安房 館山市 沖ノ島)採集日: 1929/4/10採集者:整理番号: JH043284国立科学博物館整理番号: TNS-AL-15932

Flow chart showing selection of articles.

<p>LASIK = laser in situ keratomileusis; SMILE = small incision lenticule extraction; FLEx = femtosecond lenticule extraction; RCTs = randomized controlled trials.</p> <p><i>From</i>: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). <i>P</i>referred <i>R</i>eporting <i>I</i>tems for <i>S</i>ystematic Reviews and <i>M</i>eta-<i>A</i>nalyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:<a href="http://dx.doi.org/10.1371/journal.pmed1000097" target="_blank">10.1371/journal.pmed1000097</a></p> <p>For more information, visit <a href="http://www.prisma-statement.org" target="_blank">www.prisma-statement.org</a>.</p

Subgroup Analyses on Study Design.

<p>BSCVA = best spectacle corrected visual acuity, UCVA = uncorrected visual acuity, SE = spherical equivalent, RCT = randomized controlled trials, OR = odds ratio, MD = mean difference, CI = confidence interval, I² = extent of inconsistency.</p

Alteration of the sphingolipid metabolism under MAA-BSA treatment in WERI-Rb1 cells.

<p><b>(A)</b> The sphingolipid pathway depicting the gene symbols of the enzymes involved (complete protein names in <b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0200739#pone.0200739.s002" target="_blank">S2 Table</a></b>). <b>(B-H)</b> Cells were treated with 80 μg/mL of BSA or MAA-BSA for 24 h, and gene expression or lipid levels were measured. <b>(B)</b> Genes from the <i>de novo</i> and salvage ceramide synthesis pathways. <b>(C)</b> Genes involved in the synthesis of SM from ceramides, and synthesis of glucosylceramides (GlcCer) and galactosylceramides (GalCer), both hexosylceramides (HexCer). <b>(D)</b> Genes involved in the generation of ceramide by sphingomyelin (SM) hydrolysis. <b>(E)</b> Ceramide (Cer) species levels. <b>(F)</b> SM species levels; only results from most abundant species are shown. <b>(G)</b> Ratio of total ceramide to total SM levels. <b>(H)</b> Ratio of total ceramide to total HexCer levels. Each value corresponds to the mean ± SEM of six-fold independently performed replicates evaluated in two batches. Statistics: Linear regression adjusted for batch of analysis; ***p<0.001, **p<0.01, *p<0.05.</p

Cell survival and alteration of the stress response under MAA-BSA treatment in WERI-Rb1 cells.

<p><b>(A)</b> Schematic structure of MDHDC (4-methyl-1,4-dihydropyridine-3,5-dicarbaldehyde), the most prominent adduct in malondialdehyde-acetaldehyde (MAA) protein modifications. <b>(B-C)</b> Cells treated with 20 or 80 μg/mL of BSA or MAA-BSA for 24 h. <b>(B)</b> Cell viability (%) measured by MTT assay; the repetition with the highest value was considered as 100% (each value corresponds to the mean ± SEM of six-fold independently performed replicates). <b>(C)</b> Gene expression of NAD(P)H dehydrogenase [quinone] 1 (<i>NQO1</i>) and Heme oxygenase 1 (<i>HMOX1</i>) (each value corresponds to the mean ± SEM of three-fold independently performed replicates). Statistics: 2-way ANOVA and simple effect test (when significant interaction). ***p<0.001, **p<0.01.</p